English

CRISPR THERAPEUTICS AG

EDGAR

CRSP Current report (8-K) · filed 2026-10-19

Annual consolidated revenue for 2025: about USD 3.51M, using the latest reported figures. The previous period, 2024, was about USD 37.31M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

10.2 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 10181000 USD Source

Operating margin

-1,151.84%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -117269000 USD Source
Revenue: 10181000 USD Source

Operating cash flow

-83.5 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -192395000 USD Source
Operating Cash Flow: -108897000 USD Source

Free cash flow

-84.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -192395000 USD Source
Operating Cash Flow: -108897000 USD Source
Capital Expenditure: 1152000 USD Source
Capital Expenditure: 504000 USD Source

Cash and cash equivalents: 291 million USD 2026-06-30 Source
Exact value

291337000 USD
Long-term debt including current maturities: 586 million USD 2026-06-30 Source
Exact value

586198000 USD
Shares outstanding: 96.7 million shares 2026-06-30 Source
Exact value

96660959 shares

Reported share-count change

9.37% · 8.28 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

88376439 shares · 2025-06-30· Source
96660959 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

13.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 889000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 3510000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 2646000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 1458000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 10181000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-451 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -106441000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -581599000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -450986000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -122931000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -91154000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-370 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -252461000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -167827000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -345014000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -252461000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -108897000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -192395000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -108897000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.74 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 323000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 914000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 504000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1152000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 504000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-371 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -252461000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -167827000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -345014000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -252461000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -108897000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -192395000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -108897000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 323000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 914000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 397000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 504000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1152000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 504000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-19.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-90.6%

Prior period

USD 37.31 million

2024-01-01 – 2024-12-31
Current period

USD 3.51 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

3510000 − 37314000 = -33804000 USD

37314000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
3510000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Year-over-year change in Revenue: -33804000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 3510000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2212954 Filing: 000119312526048957 Input fundies:Revenue: 37314000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2214701 Filing: 000119312526048957
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 215.35 million

Prior period

−USD 366.25 million

2024-01-01 – 2024-12-31
Current period

−USD 581.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-581599000 − -366252000 = -215347000 USD

-366252000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-581599000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Year-over-year change in Net income: -215347000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -581599000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2594151 Filing: 000119312526048957 Input fundies:NetIncome: -366252000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2512816 Filing: 000119312526048957
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 202.24 million

Prior period

−USD 142.77 million

2024-01-01 – 2024-12-31
Current period

−USD 345.01 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-345014000 − -142774000 = -202240000 USD

-142774000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-345014000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Year-over-year change in Operating cash flow: -202240000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -345014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2690526 Filing: 000119312526048957 Input fundies:OperatingCashFlow: -142774000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2692407 Filing: 000119312526048957
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-51.9%

Prior period

USD 1.9 million

2024-01-01 – 2024-12-31
Current period

USD 914,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

914000 − 1901000 = -987000 USD

1901000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
914000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Year-over-year change in Capital expenditure: -987000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 914000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2700137 Filing: 000119312526048957 Input fundies:CapitalExpenditure: 1901000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2701901 Filing: 000119312526048957
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 3.51 million 100% of revenue
Operating costs Derived USD 668.08 million 19,034% of revenue
Operating income −USD 664.57 million −18,934% of revenue
Tax, interest and other Derived −USD 82.97 million −2,364% of revenue
Net income −USD 581.6 million −16,570% of revenue

Cash

Operating cash flow −USD 345.01 million −9,829% of revenue
Capital expenditure USD 914,000 26% of revenue
Free cash flow Derived −USD 345.93 million −9,855% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,419% of revenue.
2017 Operating loss: operating costs were 258% of revenue.
2018 Operating loss: operating costs were 5,188% of revenue.
2019 Net income was higher than operating income, so the split is not drawn.
2020 Operating loss: operating costs were 49,396% of revenue.
2021 Net income was higher than operating income, so the split is not drawn.
2022 Operating loss: operating costs were 56,290% of revenue.
2023 Operating loss: operating costs were 160% of revenue.
2024 Operating loss: operating costs were 1,350% of revenue.
2025 Operating loss: operating costs were 19,034% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	5164000	73294000 Derived	-68130000	-44953000 Derived	-23177000	-55876000 Derived	Source 2016-01-01 – 2016-12-31: 5164000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -68130000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -23177000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -52860000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3016000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	40997000	105645000 Derived	-64648000	3709000 Derived	-68357000	-77907000 Derived	Source 2017-01-01 – 2017-12-31: 40997000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -64648000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -68357000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -70093000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 7814000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	3124000	162067000 Derived	-158943000	6038000 Derived	-164981000	-99012000 Derived	Source 2018-01-01 – 2018-12-31: 3124000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -158943000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -164981000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -96239000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2773000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	289590000	242850000 Derived	46740000	-20118000 Derived	66858000	49993000 Derived	Source 2019-01-01 – 2019-12-31: 289590000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 46740000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 66858000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 56677000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 6684000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	719000	355154000 Derived	-354435000	-5570000 Derived	-348865000	-256724000 Derived	Source 2020-01-01 – 2020-12-31: 719000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -354435000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -348865000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -238366000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 18358000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	914963000	541435000 Derived	373528000	-4133000 Derived	377661000	457267000 Derived	Source 2021-01-01 – 2021-12-31: 914963000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 373528000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 377661000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 538972000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 81705000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1198000	674359000 Derived	-673161000	-22986000 Derived	-650175000	-532929000 Derived	Source 2022-01-01 – 2022-12-31: 1198000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -673161000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -650175000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -495741000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 37188000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	371206000	593744000 Derived	-222538000	-68928000 Derived	-153610000	-269845000 Derived	Source 2023-01-01 – 2023-12-31: 371206000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -222538000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -153610000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -260375000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 9470000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	37314000	503880000 Derived	-466566000	-100314000 Derived	-366252000	-144675000 Derived	Source 2024-01-01 – 2024-12-31: 37314000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -466566000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -366252000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -142774000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1901000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	3510000	668081000 Derived	-664571000	-82972000 Derived	-581599000	-345928000 Derived	Source 2025-01-01 – 2025-12-31: 3510000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -664571000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -581599000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -345014000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 914000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	5164000	Revenue: 5164000 Open source
20172017-12-31	Revenue	40997000	Revenue: 40997000 Open source
20182018-12-31	Revenue	3124000	Revenue: 3124000 Open source
20192019-12-31	Revenue	289590000	Revenue: 289590000 Open source
20202020-12-31	Revenue	719000	Revenue: 719000 Open source
20212021-12-31	Revenue	914963000	Revenue: 914963000 Open source
20222022-12-31	Revenue	1198000	Revenue: 1198000 Open source
20232023-12-31	Revenue	371206000	Revenue: 371206000 Open source
20242024-12-31	Revenue	37314000	Revenue: 37314000 Open source
20252025-12-31	Revenue	3510000	Revenue: 3510000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-90.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	1,990.7%	Revenue: 5164000 Open source Revenue: 247000 Open source
20172017-12-31	Year over year	693.9%	Revenue: 40997000 Open source Revenue: 5164000 Open source
20182018-12-31	Year over year	-92.4%	Revenue: 3124000 Open source Revenue: 40997000 Open source
20192019-12-31	Year over year	9,169.8%	Revenue: 289590000 Open source Revenue: 3124000 Open source
20202020-12-31	Year over year	-99.8%	Revenue: 719000 Open source Revenue: 289590000 Open source
20212021-12-31	Year over year	127,154.9%	Revenue: 914963000 Open source Revenue: 719000 Open source
20222022-12-31	Year over year	-99.9%	Revenue: 1198000 Open source Revenue: 914963000 Open source
20232023-12-31	Year over year	30,885.5%	Revenue: 371206000 Open source Revenue: 1198000 Open source
20242024-12-31	Year over year	-89.9%	Revenue: 37314000 Open source Revenue: 371206000 Open source
20252025-12-31	Year over year	-90.6%	Revenue: 3510000 Open source Revenue: 37314000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -18,933.6% 2025

Net margin -16,569.8% 2025

Free cash flow margin -9,855.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-1,319.3%	Operating Income: -68130000 Open source Revenue: 5164000 Open source
20172017-12-31	Operating margin	-157.7%	Operating Income: -64648000 Open source Revenue: 40997000 Open source
20182018-12-31	Operating margin	-5,087.8%	Operating Income: -158943000 Open source Revenue: 3124000 Open source
20192019-12-31	Operating margin	16.1%	Operating Income: 46740000 Open source Revenue: 289590000 Open source
20202020-12-31	Operating margin	-49,295.5%	Operating Income: -354435000 Open source Revenue: 719000 Open source
20212021-12-31	Operating margin	40.8%	Operating Income: 373528000 Open source Revenue: 914963000 Open source
20222022-12-31	Operating margin	-56,190.4%	Operating Income: -673161000 Open source Revenue: 1198000 Open source
20232023-12-31	Operating margin	-60%	Operating Income: -222538000 Open source Revenue: 371206000 Open source
20242024-12-31	Operating margin	-1,250.4%	Operating Income: -466566000 Open source Revenue: 37314000 Open source
20252025-12-31	Operating margin	-18,933.6%	Operating Income: -664571000 Open source Revenue: 3510000 Open source
20162016-12-31	Net margin	-448.8%	Net Income: -23177000 Open source Revenue: 5164000 Open source
20172017-12-31	Net margin	-166.7%	Net Income: -68357000 Open source Revenue: 40997000 Open source
20182018-12-31	Net margin	-5,281.1%	Net Income: -164981000 Open source Revenue: 3124000 Open source
20192019-12-31	Net margin	23.1%	Net Income: 66858000 Open source Revenue: 289590000 Open source
20202020-12-31	Net margin	-48,520.9%	Net Income: -348865000 Open source Revenue: 719000 Open source
20212021-12-31	Net margin	41.3%	Net Income: 377661000 Open source Revenue: 914963000 Open source
20222022-12-31	Net margin	-54,271.7%	Net Income: -650175000 Open source Revenue: 1198000 Open source
20232023-12-31	Net margin	-41.4%	Net Income: -153610000 Open source Revenue: 371206000 Open source
20242024-12-31	Net margin	-981.5%	Net Income: -366252000 Open source Revenue: 37314000 Open source
20252025-12-31	Net margin	-16,569.8%	Net Income: -581599000 Open source Revenue: 3510000 Open source
20162016-12-31	Free cash flow margin	-1,082%	Revenue: 5164000 Open source Operating Cash Flow: -52860000 Open source Capital Expenditure: 3016000 Open source
20172017-12-31	Free cash flow margin	-190%	Revenue: 40997000 Open source Operating Cash Flow: -70093000 Open source Capital Expenditure: 7814000 Open source
20182018-12-31	Free cash flow margin	-3,169.4%	Revenue: 3124000 Open source Operating Cash Flow: -96239000 Open source Capital Expenditure: 2773000 Open source
20192019-12-31	Free cash flow margin	17.3%	Revenue: 289590000 Open source Operating Cash Flow: 56677000 Open source Capital Expenditure: 6684000 Open source
20202020-12-31	Free cash flow margin	-35,705.7%	Revenue: 719000 Open source Operating Cash Flow: -238366000 Open source Capital Expenditure: 18358000 Open source
20212021-12-31	Free cash flow margin	50%	Revenue: 914963000 Open source Operating Cash Flow: 538972000 Open source Capital Expenditure: 81705000 Open source
20222022-12-31	Free cash flow margin	-44,484.9%	Revenue: 1198000 Open source Operating Cash Flow: -495741000 Open source Capital Expenditure: 37188000 Open source
20232023-12-31	Free cash flow margin	-72.7%	Revenue: 371206000 Open source Operating Cash Flow: -260375000 Open source Capital Expenditure: 9470000 Open source
20242024-12-31	Free cash flow margin	-387.7%	Revenue: 37314000 Open source Operating Cash Flow: -142774000 Open source Capital Expenditure: 1901000 Open source
20252025-12-31	Free cash flow margin	-9,855.5%	Revenue: 3510000 Open source Operating Cash Flow: -345014000 Open source Capital Expenditure: 914000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -345M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-52860000	Operating Cash Flow: -52860000 Open source
20172017-12-31	Operating cash flow	-70093000	Operating Cash Flow: -70093000 Open source
20182018-12-31	Operating cash flow	-96239000	Operating Cash Flow: -96239000 Open source
20192019-12-31	Operating cash flow	56677000	Operating Cash Flow: 56677000 Open source
20202020-12-31	Operating cash flow	-238366000	Operating Cash Flow: -238366000 Open source
20212021-12-31	Operating cash flow	538972000	Operating Cash Flow: 538972000 Open source
20222022-12-31	Operating cash flow	-495741000	Operating Cash Flow: -495741000 Open source
20232023-12-31	Operating cash flow	-260375000	Operating Cash Flow: -260375000 Open source
20242024-12-31	Operating cash flow	-142774000	Operating Cash Flow: -142774000 Open source
20252025-12-31	Operating cash flow	-345014000	Operating Cash Flow: -345014000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -345.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-55876000	Operating Cash Flow: -52860000 Open source Capital Expenditure: 3016000 Open source
20172017-12-31	Free cash flow	-77907000	Operating Cash Flow: -70093000 Open source Capital Expenditure: 7814000 Open source
20182018-12-31	Free cash flow	-99012000	Operating Cash Flow: -96239000 Open source Capital Expenditure: 2773000 Open source
20192019-12-31	Free cash flow	49993000	Operating Cash Flow: 56677000 Open source Capital Expenditure: 6684000 Open source
20202020-12-31	Free cash flow	-256724000	Operating Cash Flow: -238366000 Open source Capital Expenditure: 18358000 Open source
20212021-12-31	Free cash flow	457267000	Operating Cash Flow: 538972000 Open source Capital Expenditure: 81705000 Open source
20222022-12-31	Free cash flow	-532929000	Operating Cash Flow: -495741000 Open source Capital Expenditure: 37188000 Open source
20232023-12-31	Free cash flow	-269845000	Operating Cash Flow: -260375000 Open source Capital Expenditure: 9470000 Open source
20242024-12-31	Free cash flow	-144675000	Operating Cash Flow: -142774000 Open source Capital Expenditure: 1901000 Open source
20252025-12-31	Free cash flow	-345928000	Operating Cash Flow: -345014000 Open source Capital Expenditure: 914000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

15.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	32.5%	Total Liabilities: 112116000 Open source Total Assets: 344962000 Open source
20172017-12-31	Liabilities / assets	30.8%	Total Liabilities: 83514000 Open source Total Assets: 271346000 Open source
20182018-12-31	Liabilities / assets	19.8%	Total Liabilities: 96821000 Open source Total Assets: 489016000 Open source
20192019-12-31	Liabilities / assets	11.9%	Total Liabilities: 127327000 Open source Total Assets: 1066752000 Open source
20202020-12-31	Liabilities / assets	9%	Total Liabilities: 163732000 Open source Total Assets: 1827966000 Open source
20212021-12-31	Liabilities / assets	12.8%	Total Liabilities: 352417000 Open source Total Assets: 2751877000 Open source
20222022-12-31	Liabilities / assets	16.4%	Total Liabilities: 367578000 Open source Total Assets: 2243057000 Open source
20232023-12-31	Liabilities / assets	15.6%	Total Liabilities: 346768000 Open source Total Assets: 2229571000 Open source
20242024-12-31	Liabilities / assets	13.8%	Total Liabilities: 309954000 Open source Total Assets: 2242034000 Open source
20252025-12-31	Liabilities / assets	15.2%	Total Liabilities: 343430000 Open source Total Assets: 2265243000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	14.56×	Current Assets: 320188000 Open source Current Liabilities: 21998000 Open source
20172017-12-31	Current assets / current liabilities	17.12×	Current Assets: 248385000 Open source Current Liabilities: 14511000 Open source
20182018-12-31	Current assets / current liabilities	16.81×	Current Assets: 466395000 Open source Current Liabilities: 27746000 Open source
20192019-12-31	Current assets / current liabilities	17.29×	Current Assets: 987547000 Open source Current Liabilities: 57106000 Open source
20202020-12-31	Current assets / current liabilities	18.21×	Current Assets: 1716620000 Open source Current Liabilities: 94259000 Open source
20212021-12-31	Current assets / current liabilities	20.17×	Current Assets: 2417513000 Open source Current Liabilities: 119883000 Open source
20222022-12-31	Current assets / current liabilities	15.3×	Current Assets: 1853026000 Open source Current Liabilities: 121107000 Open source
20232023-12-31	Current assets / current liabilities	17.54×	Current Assets: 1908078000 Open source Current Liabilities: 108791000 Open source
20242024-12-31	Current assets / current liabilities	22.07×	Current Assets: 1937132000 Open source Current Liabilities: 87782000 Open source
20252025-12-31	Current assets / current liabilities	13.32×	Current Assets: 1985671000 Open source Current Liabilities: 149120000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 23.18 million Exact value Exact value: -23177000 USD 2016-01-01 – 2016-12-31: -23177000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2016-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -23177000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23177000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459019004115/crsp-20181231.xml#224052 Filing: 000156459019004115 The citation records this snapshot. The page link may show a newer release later.	−USD 52.86 million Exact value Exact value: -52860000 USD 2016-01-01 – 2016-12-31: -52860000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2016-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -52860000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52860000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459019004115/crsp-20181231.xml#281800 Filing: 000156459019004115 The citation records this snapshot. The page link may show a newer release later.	USD 3.02 million Exact value Exact value: 3016000 USD 2016-01-01 – 2016-12-31: 3016000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2016-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 3016000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3016000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459019004115/crsp-20181231.xml#282432 Filing: 000156459019004115 The citation records this snapshot. The page link may show a newer release later.	−USD 55.88 million Calculation and evidence -52860000 − 3016000 USD Exact free cash flow: -55876000 USD 2016-01-01 – 2016-12-31: -52860000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3016000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2016-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -55876000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52860000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459019004115/crsp-20181231.xml#281800 Filing: 000156459019004115 Input fundies:CapitalExpenditure: 3016000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459019004115/crsp-20181231.xml#282432 Filing: 000156459019004115 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 68.36 million Exact value Exact value: -68357000 USD 2017-01-01 – 2017-12-31: -68357000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2017-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -68357000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68357000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459020004355/crsp-10k_20191231.htm#3606483 Filing: 000156459020004355 The citation records this snapshot. The page link may show a newer release later.	−USD 70.09 million Exact value Exact value: -70093000 USD 2017-01-01 – 2017-12-31: -70093000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2017-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -70093000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70093000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459020004355/crsp-10k_20191231.htm#2720534 Filing: 000156459020004355 The citation records this snapshot. The page link may show a newer release later.	USD 7.81 million Exact value Exact value: 7814000 USD 2017-01-01 – 2017-12-31: 7814000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2017-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 7814000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7814000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459020004355/crsp-10k_20191231.htm#2731558 Filing: 000156459020004355 The citation records this snapshot. The page link may show a newer release later.	−USD 77.91 million Calculation and evidence -70093000 − 7814000 USD Exact free cash flow: -77907000 USD 2017-01-01 – 2017-12-31: -70093000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 7814000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2017-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -77907000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70093000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459020004355/crsp-10k_20191231.htm#2720534 Filing: 000156459020004355 Input fundies:CapitalExpenditure: 7814000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459020004355/crsp-10k_20191231.htm#2731558 Filing: 000156459020004355 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 164.98 million Exact value Exact value: -164981000 USD 2018-01-01 – 2018-12-31: -164981000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2018-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -164981000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -164981000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459021006074/crsp-10k_20201231.htm#4187813 Filing: 000156459021006074 The citation records this snapshot. The page link may show a newer release later.	−USD 96.24 million Exact value Exact value: -96239000 USD 2018-01-01 – 2018-12-31: -96239000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2018-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -96239000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -96239000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459021006074/crsp-10k_20201231.htm#2974183 Filing: 000156459021006074 The citation records this snapshot. The page link may show a newer release later.	USD 2.77 million Exact value Exact value: 2773000 USD 2018-01-01 – 2018-12-31: 2773000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2018-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 2773000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2773000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459021006074/crsp-10k_20201231.htm#2985215 Filing: 000156459021006074 The citation records this snapshot. The page link may show a newer release later.	−USD 99.01 million Calculation and evidence -96239000 − 2773000 USD Exact free cash flow: -99012000 USD 2018-01-01 – 2018-12-31: -96239000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2773000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2018-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -99012000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -96239000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459021006074/crsp-10k_20201231.htm#2974183 Filing: 000156459021006074 Input fundies:CapitalExpenditure: 2773000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000156459021006074/crsp-10k_20201231.htm#2985215 Filing: 000156459021006074 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 66.86 million Exact value Exact value: 66858000 USD 2019-01-01 – 2019-12-31: 66858000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2019-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: 66858000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 66858000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017022001282/crsp-20211231.htm#4226335 Filing: 000095017022001282 The citation records this snapshot. The page link may show a newer release later.	USD 56.68 million Exact value Exact value: 56677000 USD 2019-01-01 – 2019-12-31: 56677000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2019-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: 56677000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 56677000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017022001282/crsp-20211231.htm#2765965 Filing: 000095017022001282 The citation records this snapshot. The page link may show a newer release later.	USD 6.68 million Exact value Exact value: 6684000 USD 2019-01-01 – 2019-12-31: 6684000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2019-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 6684000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6684000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017022001282/crsp-20211231.htm#2776088 Filing: 000095017022001282 The citation records this snapshot. The page link may show a newer release later.	USD 49.99 million Calculation and evidence 56677000 − 6684000 USD Exact free cash flow: 49993000 USD 2019-01-01 – 2019-12-31: 56677000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 6684000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2019-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: 49993000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 56677000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017022001282/crsp-20211231.htm#2765965 Filing: 000095017022001282 Input fundies:CapitalExpenditure: 6684000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017022001282/crsp-20211231.htm#2776088 Filing: 000095017022001282 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 348.87 million Exact value Exact value: -348865000 USD 2020-01-01 – 2020-12-31: -348865000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2020-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -348865000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -348865000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003441/crsp-20221231.htm#4474222 Filing: 000095017023003441 The citation records this snapshot. The page link may show a newer release later.	−USD 238.37 million Exact value Exact value: -238366000 USD 2020-01-01 – 2020-12-31: -238366000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2020-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -238366000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -238366000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003441/crsp-20221231.htm#3000924 Filing: 000095017023003441 The citation records this snapshot. The page link may show a newer release later.	USD 18.36 million Exact value Exact value: 18358000 USD 2020-01-01 – 2020-12-31: 18358000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2020-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 18358000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18358000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003441/crsp-20221231.htm#3012275 Filing: 000095017023003441 The citation records this snapshot. The page link may show a newer release later.	−USD 256.72 million Calculation and evidence -238366000 − 18358000 USD Exact free cash flow: -256724000 USD 2020-01-01 – 2020-12-31: -238366000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 18358000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2020-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -256724000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -238366000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003441/crsp-20221231.htm#3000924 Filing: 000095017023003441 Input fundies:CapitalExpenditure: 18358000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017023003441/crsp-20221231.htm#3012275 Filing: 000095017023003441 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 377.66 million Exact value Exact value: 377661000 USD 2021-01-01 – 2021-12-31: 377661000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2021-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: 377661000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 377661000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017571/crsp-20231231.htm#3160072 Filing: 000095017024017571 The citation records this snapshot. The page link may show a newer release later.	USD 538.97 million Exact value Exact value: 538972000 USD 2021-01-01 – 2021-12-31: 538972000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2021-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: 538972000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 538972000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017571/crsp-20231231.htm#2239539 Filing: 000095017024017571 The citation records this snapshot. The page link may show a newer release later.	USD 81.71 million Exact value Exact value: 81705000 USD 2021-01-01 – 2021-12-31: 81705000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2021-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 81705000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 81705000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017571/crsp-20231231.htm#2246434 Filing: 000095017024017571 The citation records this snapshot. The page link may show a newer release later.	USD 457.27 million Calculation and evidence 538972000 − 81705000 USD Exact free cash flow: 457267000 USD 2021-01-01 – 2021-12-31: 538972000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 81705000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2021-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: 457267000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 538972000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017571/crsp-20231231.htm#2239539 Filing: 000095017024017571 Input fundies:CapitalExpenditure: 81705000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017024017571/crsp-20231231.htm#2246434 Filing: 000095017024017571 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 650.18 million Exact value Exact value: -650175000 USD 2022-01-01 – 2022-12-31: -650175000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2022-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -650175000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -650175000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017899/crsp-20241231.htm#2294537 Filing: 000095017025017899 The citation records this snapshot. The page link may show a newer release later.	−USD 495.74 million Exact value Exact value: -495741000 USD 2022-01-01 – 2022-12-31: -495741000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2022-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -495741000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -495741000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017899/crsp-20241231.htm#2548429 Filing: 000095017025017899 The citation records this snapshot. The page link may show a newer release later.	USD 37.19 million Exact value Exact value: 37188000 USD 2022-01-01 – 2022-12-31: 37188000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2022-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 37188000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 37188000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017899/crsp-20241231.htm#2557670 Filing: 000095017025017899 The citation records this snapshot. The page link may show a newer release later.	−USD 532.93 million Calculation and evidence -495741000 − 37188000 USD Exact free cash flow: -532929000 USD 2022-01-01 – 2022-12-31: -495741000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 37188000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2022-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -532929000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -495741000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017899/crsp-20241231.htm#2548429 Filing: 000095017025017899 Input fundies:CapitalExpenditure: 37188000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017899/crsp-20241231.htm#2557670 Filing: 000095017025017899 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 153.61 million Exact value Exact value: -153610000 USD 2023-01-01 – 2023-12-31: -153610000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2023-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -153610000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -153610000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2431912 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 260.38 million Exact value Exact value: -260375000 USD 2023-01-01 – 2023-12-31: -260375000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2023-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -260375000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -260375000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2694288 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	USD 9.47 million Exact value Exact value: 9470000 USD 2023-01-01 – 2023-12-31: 9470000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2023-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 9470000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9470000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2703667 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 269.85 million Calculation and evidence -260375000 − 9470000 USD Exact free cash flow: -269845000 USD 2023-01-01 – 2023-12-31: -260375000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 9470000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2023-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -269845000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -260375000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2694288 Filing: 000119312526048957 Input fundies:CapitalExpenditure: 9470000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2703667 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 366.25 million Exact value Exact value: -366252000 USD 2024-01-01 – 2024-12-31: -366252000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2024-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -366252000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -366252000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2512816 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 142.77 million Exact value Exact value: -142774000 USD 2024-01-01 – 2024-12-31: -142774000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2024-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -142774000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -142774000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2692407 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	USD 1.9 million Exact value Exact value: 1901000 USD 2024-01-01 – 2024-12-31: 1901000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2024-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 1901000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1901000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2701901 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 144.68 million Calculation and evidence -142774000 − 1901000 USD Exact free cash flow: -144675000 USD 2024-01-01 – 2024-12-31: -142774000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1901000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2024-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -144675000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -142774000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2692407 Filing: 000119312526048957 Input fundies:CapitalExpenditure: 1901000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2701901 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 581.6 million Exact value Exact value: -581599000 USD 2025-01-01 – 2025-12-31: -581599000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Net Income: -581599000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -581599000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2594151 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 345.01 million Exact value Exact value: -345014000 USD 2025-01-01 – 2025-12-31: -345014000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Operating Cash Flow: -345014000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -345014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2690526 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	USD 914,000 Exact value Exact value: 914000 USD 2025-01-01 – 2025-12-31: 914000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Capital Expenditure: 914000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 914000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2700137 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.	−USD 345.93 million Calculation and evidence -345014000 − 914000 USD Exact free cash flow: -345928000 USD 2025-01-01 – 2025-12-31: -345014000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 914000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CRISPR THERAPEUTICS AG · 2025-12-31 CRISPR THERAPEUTICS AG (edgar:1674416) Free cash flow: -345928000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:19:06Z Snapshot: fedfc96f298681d547cb7414813241b047baba953e083900631908013d367ed2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1674416?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -345014000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2690526 Filing: 000119312526048957 Input fundies:CapitalExpenditure: 914000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/crsp-20251231.htm#2700137 Filing: 000119312526048957 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

191 filings · 3,193 latest values · 3,193 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001674416, 1674416, CRSP, crspr, edgar:1674416

Also known as CRISPR THERAPEUTICS AG, CRISPR Therapeutics AG

CRISPR THERAPEUTICS AG

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation